Research Paper Volume 16, Issue 2 pp 1925—1937

Figure 1. Melatonin improves brain tissue and neuronal damage caused by stroke. (A) TTC staining reveals that Melatonin at doses of 5 and 10 mg/kg significantly reduces the volume of infarction compared to the MCAO group. (B, C) The administration of Melatonin at doses of 5 and 10 mg/kg markedly decreases neural damage score and brain water content in comparison to the MCAO group. (D) H&E and Nissl staining demonstrate that Melatonin at doses of 5 and 10 mg/kg mitigates neuronal damage when compared to the MCAO group, with a more pronounced effect observed at a dose of 10 mg/kg. (E) CCK-8 assay indicates that treatment with Melatonin at concentrations of 0.5 and 1 mM enhances HT-22 cell viability relative to the OGD/R group. (F) The EdU and TUNEL assay indicate that treatment with Melatonin at concentrations of 0.5 and 1 mM enhances HT-22 proliferation and apoptosis relative to the OGD/R group. (G) DCFH-DA staining shows that exposure to Melatonin at concentrations of 0.5 and 1 mM reduces ROS levels compared to the OGD/R group. The data are presented as mean ± SD. Statistical significance is denoted by ^*P < 0.05 versus either the Con groups, ^#P < 0.05 versus either the MCAO or OGD/R groups.